Literature DB >> 27611310

CHRNA4 and ANKK1 Polymorphisms Influence Smoking-Induced Nicotinic Acetylcholine Receptor Upregulation.

Irina Esterlis1, Ansel T Hillmer2, Frederic Bois2, Brian Pittman3, Erin McGovern3, Stephanie S O'Malley3, Marina R Picciotto3, Bao-Zhu Yang4, Joel Gelernter4, Kelly P Cosgrove5.   

Abstract

INTRODUCTION: Tobacco smoking leads to increased numbers of β2*-containing nicotinic acetylcholine receptors (β2*-nAChRs) throughout the brain, which return to nonsmoker levels over extended abstinence. The goal of the current study was to determine whether the degree of tobacco smoking-induced changes in β2*-nAChR availability is genetically influenced.
METHODS: In this study, 113 European Americans participated in one or two [(123)I]5-IA-85380 single photon emission computed tomography (SPECT) brain scans. Smokers (n = 58) participated in one scan at 7-9 days of abstinence and those who remained abstinent (n = 27) were imaged again at 6-8 weeks of abstinence. Age- and sex-matched nonsmokers (n = 55) participated in one scan. Blood samples were collected for DNA analysis and genotyped for single nucleotide polymorphisms (SNPs) in the CHRNA4 and ANKK1 gene loci. β2*-nAChR availability was measured in the thalamus, striatum, cortical regions, and cerebellum.
RESULTS: The CHRNA4 SNP rs2236196 and ANKK1 SNP rs4938015 were associated with significantly higher cerebellar and cortical β2*-nAChR availability in smokers versus nonsmokers for specific genotypes. There were no significant differences by carrier status in the change in β2*-nAChR availability in smokers from 7-9 days to 6-8 weeks of abstinence.
CONCLUSION: This study provides evidence for genetic regulation of tobacco smoking-induced changes in β2*-nAChR availability and suggests that β2*-nAChR availability could be an endophenotype mediating influences of CHRNA4 variants on nicotine dependence. These results highlight individual differences in the neurochemistry of nicotine dependence and may suggest the need for individualized programs for smoking cessation. IMPLICATIONS: This study demonstrates genetic regulation of smoking-induced changes in β2*-nAChRs throughout the brain and highlights the need for personalized programs for smoking cessation.
© The Author 2016. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27611310      PMCID: PMC4978979          DOI: 10.1093/ntr/ntw081

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  45 in total

Review 1.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

2.  Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

3.  Association of CHRNA4 polymorphisms with smoking behavior in two populations.

Authors:  Shizhong Han; Bao-Zhu Yang; Henry R Kranzler; David Oslin; Raymond Anton; Joel Gelernter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-03-28       Impact factor: 3.568

4.  Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.

Authors:  M E Benwell; D J Balfour; J M Anderson
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

5.  Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence.

Authors:  Pingxing Xie; Henry R Kranzler; Michael Krauthammer; Kelly P Cosgrove; David Oslin; Raymond F Anton; Lindsay A Farrer; Marina R Picciotto; John H Krystal; Hongyu Zhao; Joel Gelernter
Journal:  Biol Psychiatry       Date:  2011-06-17       Impact factor: 13.382

6.  Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in nonhuman primates.

Authors:  Sami S Zoghbi; Gilles Tamagnan; Masahiro Fujita; Ronald M Baldwin; Mohammed S Al-Tikriti; Louis Amici; John P Seibyl; Robert B Innis
Journal:  Nucl Med Biol       Date:  2001-01       Impact factor: 2.408

Review 7.  Sex differences in nicotine effects and self-administration: review of human and animal evidence.

Authors:  K A Perkins; E Donny; A R Caggiula
Journal:  Nicotine Tob Res       Date:  1999-12       Impact factor: 4.244

8.  An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar.

Authors:  J M Roll; S T Higgins; G J Badger
Journal:  J Appl Behav Anal       Date:  1996

9.  CHRNA4 and tobacco dependence: from gene regulation to treatment outcome.

Authors:  Kent E Hutchison; David L Allen; Francesca M Filbey; Christopher Jepson; Caryn Lerman; Neal L Benowitz; Jerry Stitzel; Angela Bryan; John McGeary; Heather M Haughey
Journal:  Arch Gen Psychiatry       Date:  2007-09

10.  Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood.

Authors:  Kenneth A Perkins; Caryn Lerman; Amy Grottenthaler; Melinda M Ciccocioppo; Melissa Milanak; Cynthia A Conklin; Andrew W Bergen; Neal L Benowitz
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

View more
  5 in total

1.  Reduced α4 subunit expression in α4+- and α4+- /β2+- nicotinic acetylcholine receptors alters α4β2 subtype up-regulation following chronic nicotine treatment.

Authors:  Milena Moretti; Francesca Fasoli; Cecilia Gotti; Michael J Marks
Journal:  Br J Pharmacol       Date:  2017-08-01       Impact factor: 8.739

Review 2.  Biological determinants impact the neurovascular toxicity of nicotine and tobacco smoke: A pharmacokinetic and pharmacodynamics perspective.

Authors:  Sabrina Rahman Archie; Sejal Sharma; Elizabeth Burks; Thomas Abbruscato
Journal:  Neurotoxicology       Date:  2022-02-09       Impact factor: 4.294

3.  Partial and full deletion of nicotinic acetylcholine receptor α4 and β2 subunits reduces sensitivity to acute nicotine administration and development of tolerance following chronic nicotine administration.

Authors:  Michael J Marks; Esteban Loetz; Nick C Ortiz; Penelope A Herder; Allan C Collins
Journal:  Behav Pharmacol       Date:  2020-10       Impact factor: 2.277

Review 4.  Genetics of addictive behavior: the example of nicotine dependence.

Authors:  Philip Gorwood; Yann Le Strat; Nicolas Ramoz
Journal:  Dialogues Clin Neurosci       Date:  2017-09       Impact factor: 5.986

Review 5.  Clinical neuropsychiatric considerations regarding nonsubstance or behavioral addictions.

Authors:  Marc N Potenza
Journal:  Dialogues Clin Neurosci       Date:  2017-09       Impact factor: 5.986

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.